Spironolactone revisited.
作者信息
Polyzos Stergios A, Kountouras Jannis, Zavos Christos, Deretzi Georgia
出版信息
J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.
Abstract
摘要
相似文献
1
Spironolactone revisited.
J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.
2
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.
J Clin Hypertens (Greenwich). 2010 Sep;12(9):753-5. doi: 10.1111/j.1751-7176.2010.00339.x. Epub 2010 Jul 8.
3
[Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome].
J Bras Nefrol. 2013 Jan-Mar;35(1):69-72. doi: 10.5935/01012800.20130011.
4
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.
5
False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system?
Hypertension. 2003 Feb;41(2):193-6. doi: 10.1161/01.hyp.0000049882.23078.eb.
6
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
J Hypertens. 2013 Jan;31(1):3-15. doi: 10.1097/HJH.0b013e3283599b6a.
7
Spontaneous, L-arginine-induced and spironolactone-induced regression of protein remodeling of the left ventricle in L-NAME-induced hypertension.
Physiol Res. 2007;56 Suppl 2:S55-S62. doi: 10.33549/physiolres.931398. Epub 2007 Sep 5.
8
Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness.
Pharmacol Rep. 2011;63(4):975-82. doi: 10.1016/s1734-1140(11)70613-2.
9
Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension.
Physiol Res. 2007;56 Suppl 2:S25-S32. doi: 10.33549/physiolres.931394. Epub 2007 Sep 5.
10
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Am J Kidney Dis. 2005 Jul;46(1):94-101. doi: 10.1053/j.ajkd.2005.03.005.
引用本文的文献
1
Update on the Complications and Management of Liver Cirrhosis.
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
本文引用的文献
1
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.
J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):498-503. doi: 10.1177/1470320311402110. Epub 2011 Mar 24.
2
Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.
Eur J Endocrinol. 2011 Mar;164(3):389-95. doi: 10.1530/EJE-10-0709. Epub 2010 Dec 13.
3
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.
J Clin Hypertens (Greenwich). 2010 Sep;12(9):753-5. doi: 10.1111/j.1751-7176.2010.00339.x. Epub 2010 Jul 8.
4
Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.
Endocrinology. 2010 May;151(5):2040-9. doi: 10.1210/en.2009-0869. Epub 2010 Mar 8.
5
Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
Clin Exp Hypertens. 2009 Nov;31(8):648-56. doi: 10.3109/10641960903407017.
6
Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
Clin Nephrol. 2009 Dec;72(6):449-56. doi: 10.5414/cnp72449.
7
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.
8
Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.
Br J Clin Pharmacol. 2009 Oct;68(4):634-7. doi: 10.1111/j.1365-2125.2009.03483.x.
9
Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Circ Heart Fail. 2009 Jul;2(4):370-6. doi: 10.1161/CIRCHEARTFAILURE.108.821199.
10
Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
Curr Mol Med. 2009 Apr;9(3):299-314. doi: 10.2174/156652409787847191.
Zotero 插件